Abnormalities of myeloid progenitor cells after "successful" bone marrow transplantation.

Li, S.; Champlin, Richard E.; Fitchen, John H.; Gale, Robert Peter

doi:10.1172/jci111679

Cited by 44 publications

(19 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[46][47][48][49] While the precursor frequencies increased over time in recipients post transplant, they rarely ever returned to normal levels, continuing to remain 20-40% of that of the donor population even 3 years later. 49 In patients undergoing autologous stem cell transplant, CFU-GMs and erythroid burst-forming units (BFU-E) may take up to 2 years to reach pre-graft levels, erythroid CFUs (CFU-E) up to 4 years to recover, and megakaryocyte CFUs (CFU-Meg) even longer.…”

Section: Discussionmentioning

confidence: 99%

Measurable immune dysfunction and telomere attrition in long-term allogeneic transplant recipients

Lewis

Mullaney

Mangan

et al. 2004

Bone Marrow Transplant

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Measurable immune dysfunction and telomere attrition in long-term allogeneic transplant recipients

Lewis

Mullaney

Mangan

et al. 2004

Bone Marrow Transplant

View full text Add to dashboard Cite

“…The presence of a reduced number of committed progenitor cells despite normal peripheral blood cell counts has been described after both allogeneic 4,19,20 and autologous bone marrow transplantation. 5,6,21 It is already well known that there is a correlation between the number of cycles of radio/chemotherapy and depletion of the stem cell compartment.…”

Section: Discussionmentioning

confidence: 99%

“…A large number of authors have found a decrease in colony-forming unit (CFU-C) levels in both allogeneic and autologous bone marrow recipients (ABMT) a long time after transplant (up to 8.5 years). 4,5 Domenech et al 6 found an impairment in the long-term cultures of 33 patients after autologous bone marrow transplantation: the defect involved both CFU-C output and stromal cell formation. Using different techniques, van den Berg et al 7 and O'Flaherty et al 8 clearly demonstrated that a stromal cell compartment defect is always present after allogeneic bone marrow transplantation.…”

mentioning

confidence: 99%

Haematopoietic abnormalities after autologous stem cell transplantation in lymphoma patients

Soligo

Deliliers

Servida

et al. 1998

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Haematopoietic reconstitution after autologous stem cell transplantation (ASCT) was evaluated at different times in 26 lymphoma patients. All of the patients showed a significant decrease in the number of both committed (CFU-C) and more primitive progenitor cells (LTC-IC). The expansion of bone marrow progenitor cells in a 'stroma-free' long-term liquid culture system supplemented with SCF, IL-3, IL-6 and GM-CSF from 19 transplanted patients was significantly reduced compared to normal controls. The stromal cell compartment, evaluated by means of a CFU-F assay, was also greatly reduced. The number of haematopoietic and stromal cell progenitors was, nevertheless, very similar to their pre-transplant values. Bone marrow histology, which was evaluated at different times after transplant, showed an increase in reticulin fibres, the dilatation of parenchymal sinusoids and some morphological evidence of trilineage dysplasia in 11 patients; however, the same abnormalities were seen in the majority of pretransplant samples. No cytogenetic abnormalities were observed in 15 patients before transplant, but four subsequently developed persistent clonal karyotypic alterations and five showed non-clonal abnormalities that generally disappeared over time. Our data suggest that both the stromal and the haematopoietic compartments are somehow damaged after ASCT for lymphoma; however, these defects generally pre-exist the transplant conditioning regimen and seem to become less pronounced over time. Keywords: bone marrow transplantation; cytogenetics; haematopoietic stem cells; stromal cells High-dose chemo-radiotherapy followed by the infusion of cryo-preserved autologous bone marrow or peripheral blood stem cells has been increasingly used for the treatment of a variety of malignant haematopoietic diseases. 1After the pancytopenic period, the majority of patients recover normal peripheral blood counts and tend to maintain them for many years after the transplant.2,3 However,

show abstract

“…13 Abnormalities in haematopoiesis have been shown following transplantation. [14][15][16][17] Decreased bone marrow cellularity has been shown to persist up to 3 years following allogeneic transplantation. 18 The number of colony-forming units (CFU-GM, BFU-E, CFU-Meg and TL-CFU) was shown to be diminished following autologous transplantation persisting for as long as 4-5 years.…”

mentioning

confidence: 99%

Long-term haematological recovery following high-dose chemotherapy with autologous bone marrow transplantation or peripheral stem cell transplantation in patients with solid tumours

Nieboer

Vries

Mulder

et al. 2001

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Long-term peripheral blood counts and factors influencing long-term trilineage haematological recovery of consecutive patients in a single institution treated with high-dose chemotherapy (HDC) and ABMT or PSCT for solid tumours were examined. Patients with a relapse-free survival of Ͼ1 year were included in the analysis (n = 131). Peripheral blood counts were examined 6 months and yearly following transplantation. Median follow-up was 4.1 years (range 1-10+ years). Three years after transplantation 91% of patients had normal white blood counts (WBC), 94% normal haemoglobin (Hb) and 75% normal platelets. Trilineage recovery was complete in 70% (n = 83) at 3 years and 85% pheral blood has been increasingly applied for a variety of disorders. Autologous bone marrow transplantation (ABMT) or peripheral stem cell transplantation (PSCT) permits the delivery of a higher, marrow-ablative dose of chemotherapy. In addition to patients with haematological diseases an increasing number of patients with solid tumours have undergone HDC with ABMT or PSCT during the last decade. 1 HDC with ABMT or PSCT is not considered standard treatment for solid tumours, therefore benefits have to be studied in randomised studies and balanced against the risks of the treatment, both in the short and long term. 2 Solid tumours treated with HDC followed by ABMT or PSCT include breast cancer, 3,4 ovarian carcinoma, 5-7 relapsed germ cell tumours 8-10 and childhood sarcomas. 11,12 In the last decade, a shift from bone marrow to peripheral blood as the source of haematopoietic stem cells has occurred. It has been shown that PSCT compared to ABMT offers faster short-term recovery of peripheral blood counts resulting in lower morbidity, mostly due to fewer infections and haemorrhagic periods and a reduced usage of blood products. 13 Abnormalities in haematopoiesis have been shown following transplantation. 14-17 Decreased bone marrow cellularity has been shown to persist up to 3 years following allogeneic transplantation. 18 The number of colony-forming units (CFU-GM, BFU-E, CFU-Meg and TL-CFU) was shown to be diminished following autologous transplantation persisting for as long as 4-5 years. [19][20][21][22] Patients relapsing after transplantation showed decreased haematological tolerance to reinduction chemotherapy. 23 Radiotherapy after transplantation and infections during followup can lead to haematopoietic stress and temporary cytopenias have been described in such circumstances. 24 Clinical problems could therefore arise from the abnormalities in haematopoiesis following autologous transplantation.Data about attaining and maintaining sustained long-term (ie Ͼ1 year) haematopoiesis following ABMT or PSCT are scarce. Some data are available from patients with haematological malignancies and/or after allogeneic transplantation with, in general, a follow-up of 1 year at the most. 18,25,26 Studies usually report that peripheral blood counts will normalise within 1 year after transplantation. 21,23,24,[27][28][29][30][31][32] Factors in...

show abstract

Abnormalities of myeloid progenitor cells after "successful" bone marrow transplantation.

Cited by 44 publications

References 27 publications

Measurable immune dysfunction and telomere attrition in long-term allogeneic transplant recipients

Measurable immune dysfunction and telomere attrition in long-term allogeneic transplant recipients

Haematopoietic abnormalities after autologous stem cell transplantation in lymphoma patients

Long-term haematological recovery following high-dose chemotherapy with autologous bone marrow transplantation or peripheral stem cell transplantation in patients with solid tumours

Contact Info

Product

Resources

About